Zivo Bioscience, Inc. (ZIVOW) — SEC Filings
Zivo Bioscience, Inc. (ZIVOW) — 32 SEC filings. Latest: 8-K (Dec 23, 2025). Includes 17 8-K, 6 10-Q, 2 DEF 14A.
View Zivo Bioscience, Inc. on SEC EDGAR
Overview
Zivo Bioscience, Inc. (ZIVOW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 23, 2025: Zivo Bioscience, Inc. filed an 8-K on December 23, 2025, reporting events as of December 19, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes fi
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 7 bearish, 25 neutral. The dominant filing sentiment for Zivo Bioscience, Inc. is neutral.
Filing Type Overview
Zivo Bioscience, Inc. (ZIVOW) has filed 17 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13D/A, 2 SC 13D, 1 8-K/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of ZIVOW's 27 recent filings, 5 were flagged as high-risk, 18 as medium-risk, and 4 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $119,025 |
| Net Income | -$6,884,474 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $57,222 |
| Operating Margin | N/A |
| Total Assets | $559,452 |
| Total Debt | $3,846,055 |
Key Executives
- Laith Yaldoo
- Keith Marchiando
- Mark E. Strome
Industry Context
Zivo Bioscience operates in the biotechnology sector, which is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The industry is highly competitive, with companies vying for market share through innovation and strategic partnerships. Recent trends include a focus on specialized therapeutics and diagnostics, requiring substantial capital investment for research and clinical trials.
Top Tags
corporate-governance (4) · management-change (3) · financials (3) · biotech (3) · 10-Q (3) · ownership-change (3) · amendment (3) · unregistered-sales (3) · equity-offering (3) · dilution (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash on Hand | $57,222 | Represents a 96.3% decrease from $1,542,442 at December 31, 2024, highlighting severe liquidity issues. |
| Net Loss (Q3 2025) | $1,033,056 | A 54.5% reduction from the $2,268,597 net loss in Q3 2024, indicating some operational efficiency gains. |
| Net Loss (YTD Sep 2025) | $6,884,474 | A 41.6% improvement from the $11,783,451 net loss in YTD Sep 2024, but still a substantial loss. |
| Product Revenue (YTD Sep 2025) | $119,025 | A 77.1% increase from $67,220 in YTD Sep 2024, showing growth in core product sales. |
| General & Administrative Expenses (YTD Sep 2025) | $3,446,876 | A 61.2% decrease from $8,895,978 in YTD Sep 2024, reflecting significant cost-cutting efforts. |
| Research & Development Expenses (YTD Sep 2025) | $3,452,336 | A 19.4% increase from $2,891,452 in YTD Sep 2024, indicating continued investment in product development. |
| Accumulated Deficit | $143,851,025 | Highlights the company's long history of unprofitability and significant capital consumption. |
| Convertible Loan Proceeds | $250,000 | Initial borrowing under a new $2 million program, providing short-term liquidity but adding debt. |
| Net Loss (Q2 2025) | $1,640,232 | Significant improvement from $8,236,368 in Q2 2024, but still a substantial loss. |
| Total Revenues (Q2 2025) | $53,400 | Increase from zero in Q2 2024, showing nascent product revenue generation. |
| Net Cash Used in Operating Activities (Six Months 2025) | $1,906,648 | Continued negative cash flow from core operations, contributing to cash depletion. |
| Shares Issued for Exchange Agreements | 146,660 | Dilution to existing shareholders in exchange for future revenue share rights. |
| Future Rights Exchanged | $3,666,500 | Value of future revenue share rights cancelled through stock issuance. |
| Total Operating Lease Liabilities | $300,742 | New financial obligations from recent facility leases in Troy, MI and Fort Myers, FL. |
| Loan Payable - Current Portion | $292,919 | Short-term debt obligation for insurance premiums, due within one year. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Zivo Bioscience, Inc. (ZIVOW)?
Zivo Bioscience, Inc. has 32 recent SEC filings from Jan 2024 to Dec 2025, including 17 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ZIVOW filings?
Across 32 filings, the sentiment breakdown is: 7 bearish, 25 neutral. The dominant sentiment is neutral.
Where can I find Zivo Bioscience, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Zivo Bioscience, Inc. (ZIVOW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Zivo Bioscience, Inc.?
Key financial highlights from Zivo Bioscience, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ZIVOW?
The investment thesis for ZIVOW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Zivo Bioscience, Inc.?
Key executives identified across Zivo Bioscience, Inc.'s filings include Laith Yaldoo, Keith Marchiando, Mark E. Strome.
What are the main risk factors for Zivo Bioscience, Inc. stock?
Of ZIVOW's 27 assessed filings, 5 were flagged high-risk, 18 medium-risk, and 4 low-risk.
What are recent predictions and forward guidance from Zivo Bioscience, Inc.?
Forward guidance and predictions for Zivo Bioscience, Inc. are extracted from SEC filings as they are enriched.